The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases

AbstractBackground More than half of the metastatic breast cancer patients with brain metastases (BCBM) are HER-2 negative, and the prognosis of HER2-negative BCBM is dismal. But few clinical trials have investigated systemic therapies for this subgroup of patients.Methods This real-world study incl...

Full description

Bibliographic Details
Main Authors: Xuelian Chen, Xue Bai, Xiaofeng Xie, Jiayi Huang, Liping Chen, Lin Song, Xiaofeng Lan, Qiuyi Zhang, Jinfeng Guo, Caiwen Du
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Low-dose apatinib
brain metastases
breast cancer
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2023.2218647

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2023.2218647

Similar Items